000294929 001__ 294929
000294929 005__ 20250403112514.0
000294929 0247_ $$2doi$$a10.1093/noajnl/vdae185
000294929 0247_ $$2ISSN$$a2632-2498
000294929 0247_ $$2altmetric$$aaltmetric:173828246
000294929 0247_ $$2pmid$$apmid:39896072
000294929 037__ $$aDKFZ-2024-02636
000294929 082__ $$a610
000294929 1001_ $$0P:(DE-He78)c0538fae462bd98e3cd8d54ed885b0eb$$aPfaff, Elke$$b0$$eFirst author$$udkfz
000294929 245__ $$aPediatric spinal high-grade glioma in the pediatric precision oncology registry INFORM: identification of potential therapeutic targets
000294929 260__ $$aOxford$$bOxford University Press$$c2025
000294929 3367_ $$2DRIVER$$aarticle
000294929 3367_ $$2DataCite$$aOutput Types/Journal article
000294929 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1738658972_8588
000294929 3367_ $$2BibTeX$$aARTICLE
000294929 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000294929 3367_ $$00$$2EndNote$$aJournal Article
000294929 500__ $$a#EA:B360#LA:B360# / Volume 7, Issue 1, January-December 2025, vdae185
000294929 520__ $$aBackground: High-grade glioma (HGG) of the spinal cord constitute rare tumors in the pediatric population. Knowledge of the molecular profile of this pediatric HGG (pedHGG) subgroup is limited and the clinical outcome is poor. Therefore, the aim of this study is to provide more profound investigations of molecular characteristics and clinical features of these tumors. Methods: Between 01/2015 and 10/2023 seventeen spinal tumors with HGG histology were analyzed by the INFORM precision oncology registry. Comprehensive molecular profiling (including next-generation sequencing approaches and DNA methylation analysis) was performed. Clinical data provided by the treating centers was evaluated regarding treatment approaches and outcome. Results: Subgroup classification based on DNA methylation analysis revealed molecular HGG subgroups in 12/17 cases, while 2/17 were classified as molecular low-grade glioma (LGG) and 3/17 were not unequivocally classifiable. Typical genetic alterations described in pedHGG usually presenting at other localizations were also present in the counterparts located in the spinal cohort. Alterations which might serve as promising target for personalized therapy approaches were identified in a subset of tumors.Conclusion: With this cohort of 12 molecularly confirmed spinal pedHGG cases we provide a compilation of genomic as well as clinical features of this rare subgroup, contributing to a better understanding and eventually to future treatment approaches.
000294929 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000294929 588__ $$aDataset connected to CrossRef, Journals: inrepo02.dkfz.de
000294929 7001_ $$0P:(DE-He78)2f592d9d8339bee07cca3956b7472b61$$aSchramm, Kathrin$$b1$$udkfz
000294929 7001_ $$0P:(DE-He78)261d2b84aded878003e6e35d18113831$$aBlattner-Johnson, Mirjam$$b2$$udkfz
000294929 7001_ $$0P:(DE-He78)fae1bf941c5fd76cf5356ecfa1243cc4$$aJones, Barbara C$$b3$$udkfz
000294929 7001_ $$0P:(DE-He78)75cc815aba77c01af41fe20138617e9c$$aStark, Sebastian$$b4
000294929 7001_ $$0P:(DE-He78)e5bb26ffbde307745ae396c2e829dac5$$aBalasubramanian, Gnana Prakash$$b5$$udkfz
000294929 7001_ $$0P:(DE-He78)1bae3784eb554a693b0e7ce03a20bdb8$$aPreviti, Christopher$$b6$$udkfz
000294929 7001_ $$0P:(DE-He78)50c2928009c788a6a5f3a0708dfb6df5$$aAutry, Robert J$$b7$$udkfz
000294929 7001_ $$0P:(DE-He78)8de7015af76bd61fb0bc13bb3facb1df$$aFiesel, Petra$$b8$$udkfz
000294929 7001_ $$0P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aSahm, Felix$$b9$$udkfz
000294929 7001_ $$0P:(DE-HGF)0$$aReuss, David$$b10
000294929 7001_ $$0P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$avon Deimling, Andreas$$b11$$udkfz
000294929 7001_ $$0P:(DE-He78)a6b5fcabf661bef95109dbee87dc5271$$avan Tilburg, Cornelis M$$b12$$udkfz
000294929 7001_ $$0P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aPajtler, Kristian W$$b13$$udkfz
000294929 7001_ $$0P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f$$aMilde, Till$$b14$$udkfz
000294929 7001_ $$aDirksen, Uta$$b15
000294929 7001_ $$aKramm, Christof M$$b16
000294929 7001_ $$avon Bueren, André O$$b17
000294929 7001_ $$aMunthe-Kaas, Monica C$$b18
000294929 7001_ $$00000-0002-3931-4125$$aØra, Ingrid$$b19
000294929 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan M$$b20$$udkfz
000294929 7001_ $$0P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aWitt, Olaf$$b21$$udkfz
000294929 7001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, David$$b22$$eLast author$$udkfz
000294929 773__ $$0PERI:(DE-600)3009682-0$$a10.1093/noajnl/vdae185$$gp. vdae185$$n1$$pvdae185$$tNeuro-oncology advances$$v7$$x2632-2498$$y2025
000294929 8767_ $$8SOA24LT013257$$92024-11-15$$d2025-04-02$$eAPC$$jZahlung erfolgt$$v0.00
000294929 909CO $$ooai:inrepo02.dkfz.de:294929$$pVDB$$pOpenAPC$$popenCost
000294929 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c0538fae462bd98e3cd8d54ed885b0eb$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000294929 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2f592d9d8339bee07cca3956b7472b61$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000294929 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)261d2b84aded878003e6e35d18113831$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000294929 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fae1bf941c5fd76cf5356ecfa1243cc4$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000294929 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)75cc815aba77c01af41fe20138617e9c$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000294929 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e5bb26ffbde307745ae396c2e829dac5$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000294929 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1bae3784eb554a693b0e7ce03a20bdb8$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000294929 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)50c2928009c788a6a5f3a0708dfb6df5$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000294929 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8de7015af76bd61fb0bc13bb3facb1df$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000294929 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000294929 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000294929 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000294929 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a6b5fcabf661bef95109dbee87dc5271$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000294929 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000294929 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000294929 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b20$$kDKFZ
000294929 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aDeutsches Krebsforschungszentrum$$b21$$kDKFZ
000294929 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b22$$kDKFZ
000294929 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000294929 9141_ $$y2024
000294929 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOL ADV : 2022$$d2023-10-27
000294929 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-27
000294929 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-27
000294929 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-27
000294929 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-11-23T11:49:35Z
000294929 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-11-23T11:49:35Z
000294929 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2022-11-23T11:49:35Z
000294929 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-27
000294929 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2023-10-27
000294929 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-27
000294929 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-27
000294929 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-10-27
000294929 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-10-27
000294929 915pc $$0PC:(DE-HGF)0000$$2APC$$aAPC keys set
000294929 915pc $$0PC:(DE-HGF)0001$$2APC$$aLocal Funding
000294929 915pc $$0PC:(DE-HGF)0002$$2APC$$aDFG OA Publikationskosten
000294929 915pc $$0PC:(DE-HGF)0003$$2APC$$aDOAJ Journal
000294929 9202_ $$0I:(DE-He78)B360-20160331$$kB360$$lPädiatrische Gliomforschung$$x0
000294929 9200_ $$0I:(DE-He78)B360-20160331$$kB360$$lPädiatrische Gliomforschung$$x0
000294929 9201_ $$0I:(DE-He78)B360-20160331$$kB360$$lPädiatrische Gliomforschung$$x0
000294929 9201_ $$0I:(DE-He78)B310-20160331$$kB310$$lKKE Pädiatrische Onkologie$$x1
000294929 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x2
000294929 9201_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x3
000294929 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x4
000294929 9201_ $$0I:(DE-He78)ED01-20160331$$kED01$$lDKTK Koordinierungsstelle Essen/Düsseldorf$$x5
000294929 9201_ $$0I:(DE-He78)W610-20160331$$kW610$$lCore Facility Omics IT$$x6
000294929 980__ $$ajournal
000294929 980__ $$aVDB
000294929 980__ $$aI:(DE-He78)B360-20160331
000294929 980__ $$aI:(DE-He78)B310-20160331
000294929 980__ $$aI:(DE-He78)B062-20160331
000294929 980__ $$aI:(DE-He78)B300-20160331
000294929 980__ $$aI:(DE-He78)HD01-20160331
000294929 980__ $$aI:(DE-He78)ED01-20160331
000294929 980__ $$aI:(DE-He78)W610-20160331
000294929 980__ $$aUNRESTRICTED
000294929 980__ $$aAPC